Pharmaceutical

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential…

8 months ago

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous…

8 months ago

Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

8 months ago

iZafe Group presented at Stora Aktiedagarna

STOCKHOLM, SWEDEN / ACCESSWIRE / November 30, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group's CEO, Anders Segerström, presented the company…

8 months ago

FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement

TORONTO, ON / ACCESSWIRE / November 30, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company) and Celly…

8 months ago

Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference

Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer…

8 months ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the…

8 months ago

Poolbeg Pharma PLC Announces Directorate Change

LONDON, UK / ACCESSWIRE / November 30, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed…

8 months ago

Theralase Release’s 3Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

8 months ago

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

8 months ago